ClinicalTrials.gg
Active, not recruitingNCT02516241Updated Jul 14, 2026Results posted

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

A Phase 3 interventional study of MEDI4736 (Durvalumab) and Tremelimumab in Urothelial Cancer, sponsored by AstraZeneca. Active, not recruiting at 222 sites in 24 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,126
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer

Read the detailed description

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of MEDI4736 (Durvalumab) monotherapy and MEDI4736 (Durvalumab) in combination with tremelimumab versus SoC (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) first-line chemotherapy in treatment-naïve patients with histologically or cytologically documented, unresectable, Stage IV transitional cell carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra) and to allow sufficient flexibility for Investigators and patients to select the agents that reflect their normal clinical practice and national guidelines. The patients enrolled in the study will be randomized 1:1:1 to receive treatment with combination therapy, monotherapy, or SoC (cisplatin + gemcitabine or carboplatin + gemcitabine, based on cisplatin eligibility). Patients will be treated with MEDI4736 (Durvalumab) or MEDI4736 (Durvalumab) with tremelimumab, or treated with SoC until progressive disease (PD) is confirmed, unacceptable toxicity occurs, withdrawal of consent, or another discontinuation criterion is met. Patients will be followed for up to 2 years.

02

Conditions studied

  • Urothelial Cancer

Keywords

  • Urothelial Cancer
  • Phase III
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or cytologically documented, unresectable, Stage IV transitional cell carcinoma of the urothelium who have not been previously treated with chemotherapy.
  • Patients eligible or ineligible for cisplatin-based chemotherapy. Cisplatin ineligibility is defined as meeting 1 of the following criteria: • (calculated or measured) \<60 mL/min calculated by Cockcroft-Gault equation (using actual body weight) or by measured 24-hour urine collection for determination • (CTCAE) Grade ≥2 audiometric hearing loss • CTCAE Grade ≥2 peripheral neuropathy • ≥Class III heart failure.
  • Tumor status, with Immunohistochemical (IHC) assay confirmed by a reference laboratory, must be known prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to immune-mediated therapy, including but not limited to, other anti cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), , anti-PD-L1, or anti-PD-L2 antibodies, including therapeutic anticancer vaccines. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment.
  • History of allogenic organ transplantation that requires use of agents.
  • Active or prior documented or inflammatory disorders. The following are exceptions to this criterion: • Patients with vitiligo or alopecia • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement • Any chronic skin condition that does not require systemic therapy • Patients without active disease in the last 3 years may be included but only after consultation with AstraZeneca • Patients with celiac disease controlled by diet alone may be included but only after consultation with AstraZeneca.
  • or spinal cord compression unless the patient's condition is stable and off for at least 14 days prior to the start of study treatment. Patients with suspected or known brain metastases at screening should have an MRI (preferred)/CT, preferably with IV contrast to access baseline disease status.
  • Active infection including tuberculosis, , , or (HIV).
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of product (IP). The following are exceptions to this criterion: • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection) • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent • Steroids as premedication for reactions (eg, CT scan premedication).
  • Receipt of within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,126 participants (actual)

Study arms

  • Experimental
    Combination Therapy

    MEDI4736 (Durvalumab) + Tremelimumab

    Drug: MEDI4736 (Durvalumab) · Drug: Tremelimumab

  • Experimental
    Monotherapy

    MEDI4736 (Durvalumab)

    Drug: MEDI4736 (Durvalumab)

  • Active comparator
    Standard of Care

    Standard of Care Chemotherapy Treatment

    Drug: Cisplatin · Drug: Carboplatin · Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  2. To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

Secondary outcomes

  1. OS, Full Analysis Set - Durvalumab Monotherapy vs SoC

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  2. OS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  3. OS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  4. Alive at 24 Months (OS24), Full Analysis Set

    Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.

    Time frame: From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).

  5. Alive at 24 Months (OS24), PD-L1-High Analysis Set

    Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.

    Time frame: From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).

  6. Alive at 24 Months (OS24), PD-L1-Low/Negative Analysis Set

    Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.

    Time frame: From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).

  7. PFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  8. PFS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

    Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  9. PFS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

    Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  10. Alive and Progression-free at 12 Months (APF12), Full Analysis Set

    Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).

  11. Alive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set

    Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).

  12. Alive and Progression-free at 12 Months (APF12), PD-L1-Low/Negative Analysis Set

    Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).

  13. PFS2, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1). Median PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  14. PFS2, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

    Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1). Median PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  15. PFS2, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

    Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1). Median PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  16. Objective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  17. Objective Response Rate (ORR), PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

    Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  18. Objective Response Rate (ORR), PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

    Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  19. Objective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population

    Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR. unconfirmed responses are excluded.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (01NOV2017, a maximum of 3 years).

  20. Disease Control Rate (DCR) at 6 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).

  21. Disease Control Rate (DCR) at 6 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

    Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).

  22. Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

    Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).

  23. Disease Control Rate (DCR) at 12 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020)

  24. Disease Control Rate (DCR) at 12 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

    Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).

  25. Disease Control Rate (DCR) at 12 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

    Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).

  26. Duration of Response (DoR), Full Analysis Set

    Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  27. Duration of Response (DoR), PD-L1-High Analysis Set

    Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  28. Duration of Response (DoR), PD-L1-Low/Negative Analysis Set

    Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).

    Time frame: Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  29. Serum Concentrations of Durvalumab, Pharmacokinetic Analysis Set

    Blood samples were collected to determine the serum concentration of durvalumab.

    Time frame: Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.

  30. Serum Concentrations of Tremelimumab, Pharmacokinetic Analysis Set

    Blood samples were collected to determine the serum concentration of tremelimumab.

    Time frame: Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.

  31. Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab, Safety Analysis Set - ADA Evaluable Patients

    Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Durvalumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.

    Time frame: At week 0, 4, 12 and 24, and at follow-up Month 3.

  32. Number of Participants With Anti-Drug Antibody (ADA) Response to Tremelimumab, Safety Analysis Set - ADA Evaluable Patients

    Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Tremelimumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.

    Time frame: At week 0, 4, 12 and at follow-up Month 3.

  33. Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score. All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104). NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items "I feel weak all overall" and "I feel light-headed (dizzy)". The range of each item is 0-4. Higher score represent worse outcome.

    Time frame: At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  34. Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score. All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104). NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items "I feel weak all overall" and "I feel light-headed (dizzy)". The range of each item is 0-4. Higher score represent worse

    Time frame: At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  35. Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score. All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104). NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items "I feel weak all overall" and "I feel light-headed (dizzy)". The range of each item is 0-4. Higher score represent worse

    Time frame: At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  36. Improvement in Fatigue and Deterioration in Pain Per FACT-BL, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    Fatigue will be based on the question of "I have a lack of energy" and pain will be based on the question of "I have pain", according to GP1 and GP4 in PWB, respectively. Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL. Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.

    Time frame: At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  37. Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    Fatigue will be based on the question of "I have a lack of energy" and pain will be based on the question of "I have pain", according to GP1 and GP4 in PWB, respectively. Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL. Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.

    Time frame: At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

  38. Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

    Fatigue will be based on the question of "I have a lack of energy" and pain will be based on the question of "I have pain", according to GP1 and GP4 in PWB, respectively. Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL. Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.

    Time frame: At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).

07

Results

Posted May 13, 2021

Participant flow

Participant flow — Overall Study
MilestoneCombination TherapyMonotherapyStandard of Care
Started342346344
Received treatment340345313
Completed000
Not completed342346344
Withdrew: Death255262270
Withdrew: Lost to follow-up113
Withdrew: Withdrawal by subject2712
Withdrew: Participants ongoing at data cut-off847659

Outcome measures

PrimaryTo Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set
MonthsCombination TherapyStandard of Care
To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set15.1 (13.1 to 18.0)12.1 (10.9 to 14)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.0751 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.85 · 98.66% CI 0.688 to 1.063The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
PrimaryTo Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set
MonthsMonotherapyStandard of Care
To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set14.4 (10.4 to 17.3)12.1 (10.4 to 15.0)
Statistical analysis
  • Monotherapy vs Standard of Care · Log Rank · p = 0.3039 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.89 · 96.99% CI 0.695 to 1.139The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryOS, Full Analysis Set - Durvalumab Monotherapy vs SoC

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
OS, Full Analysis Set - Durvalumab Monotherapy vs SoC
MonthsMonotherapyStandard of Care
OS, Full Analysis Set - Durvalumab Monotherapy vs SoC13.2 (10.3 to 15)12.1 (10.9 to 14)
Statistical analysis
  • Monotherapy vs Standard of Care · Log Rank · p = 0.8637 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.99 · 95% CI 0.830 to 1.169The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryOS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
OS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC
MonthsCombination TherapyStandard of Care
OS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC17.9 (14.8 to 24.2)12.1 (10.4 to 15.0)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.0091 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.74 · 95% CI 0.589 to 0.928The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryOS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
OS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy
MonthsCombination TherapyMonotherapyStandard of Care
OS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy11.8 (8.9 to 15.8)10.9 (8.0 to 14.8)12.2 (10.4 to 14)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.7599 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 1.04 · 95% CI 0.799 to 1.359The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
  • Combination Therapy vs Monotherapy · Log Rank · p = 0.4424 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.90 · 95% CI 0.692 to 1.175The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryAlive at 24 Months (OS24), Full Analysis Set

Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.

Time frame:
From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Alive at 24 Months (OS24), Full Analysis Set
percentage of participantsCombination TherapyMonotherapyStandard of Care
Alive at 24 Months (OS24), Full Analysis Set39.0 (33.8 to 44.2)31.5 (26.6 to 36.4)29.0 (24.2 to 34.0)
SecondaryAlive at 24 Months (OS24), PD-L1-High Analysis Set

Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.

Time frame:
From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Alive at 24 Months (OS24), PD-L1-High Analysis Set
percentage of participantsCombination TherapyMonotherapyStandard of Care
Alive at 24 Months (OS24), PD-L1-High Analysis Set43.7 (36.8 to 50.3)36.0 (29.5 to 42.6)29.3 (23.1 to 35.7)
SecondaryAlive at 24 Months (OS24), PD-L1-Low/Negative Analysis Set

Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.

Time frame:
From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Alive at 24 Months (OS24), PD-L1-Low/Negative Analysis Set
percentage of participantsCombination TherapyMonotherapyStandard of Care
Alive at 24 Months (OS24), PD-L1-Low/Negative Analysis Set32.1 (24.5 to 40.0)24.5 (17.6 to 32.0)28.6 (21.2 to 36.4)
SecondaryPFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
PFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
MonthsCombination TherapyMonotherapyStandard of Care
PFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC3.7 (3.4 to 3.8)2.3 (1.9 to 3.5)6.7 (5.7 to 7.3)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.2579 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 1.10 · 95% CI 0.931 to 1.304The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
  • Monotherapy vs Standard of Care · Log Rank · p = 0.0008 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 1.33 · 95% CI 1.124 to 1.567The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryPFS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
PFS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC
MonthsCombination TherapyMonotherapyStandard of Care
PFS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC4.1 (3.6 to 5.7)2.4 (1.9 to 3.7)5.8 (5.6 to 7.2)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.2395 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.88 · 95% CI 0.705 to 1.091The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
  • Monotherapy vs Standard of Care · Log Rank · p = 0.2431 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 1.14 · 95% CI 0.917 to 1.406The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryPFS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
PFS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy
MonthsCombination TherapyMonotherapyStandard of Care
PFS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy2.0 (1.9 to 3.6)2.0 (1.9 to 3.5)7.2 (5.7 to 7.5)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.0014 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 1.53 · 95% CI 1.177 to 1.990The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
  • Combination Therapy vs Monotherapy · Log Rank · p = 0.6236 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.94 · 95% CI 0.729 to 1.209The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryAlive and Progression-free at 12 Months (APF12), Full Analysis Set

Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Alive and Progression-free at 12 Months (APF12), Full Analysis Set
percentage of participantsCombination TherapyMonotherapyStandard of Care
Alive and Progression-free at 12 Months (APF12), Full Analysis Set21.4 (17.2 to 26.0)16.8 (13.1 to 21.1)15.3 (11.4 to 19.7)
SecondaryAlive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set

Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Alive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set
percentage of participantsCombination TherapyMonotherapyStandard of Care
Alive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set25.6 (19.7 to 31.8)21.2 (15.9 to 27.0)15.0 (10.2 to 20.7)
SecondaryAlive and Progression-free at 12 Months (APF12), PD-L1-Low/Negative Analysis Set

Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Alive and Progression-free at 12 Months (APF12), PD-L1-Low/Negative Analysis Set
percentage of participantsCombination TherapyMonotherapyStandard of Care
Alive and Progression-free at 12 Months (APF12), PD-L1-Low/Negative Analysis Set15.2 (9.6 to 21.8)9.7 (5.4 to 15.7)15.6 (9.6 to 22.9)
SecondaryPFS2, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1). Median PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
PFS2, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
MonthsCombination TherapyMonotherapyStandard of Care
PFS2, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC14.6 (11.3 to 17.8)11.9 (8.9 to 14.6)11.5 (10.3 to 12.8)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.0477 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.83 · 95% CI 0.683 to 0.998The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
  • Monotherapy vs Standard of Care · Log Rank · p = 0.7885 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.97 · 95% CI 0.809 to 1.175The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryPFS2, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1). Median PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
PFS2, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC
MonthsCombination TherapyMonotherapyStandard of Care
PFS2, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC17.2 (12.1 to 24.8)13.4 (9.7 to 17.5)11.3 (8.9 to 14.3)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.0053 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.70 · 95% CI 0.549 to 0.901The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
  • Monotherapy vs Standard of Care · Log Rank · p = 0.1336 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.83 · 95% CI 0.651 to 1.059The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryPFS2, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1). Median PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
PFS2, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy
MonthsCombination TherapyMonotherapyStandard of Care
PFS2, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy10.7 (7.5 to 16.6)9.4 (7.0 to 13.7)11.6 (10.3 to 13.4)
Statistical analysis
  • Combination Therapy vs Standard of Care · Log Rank · p = 0.8148 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 1.04 · 95% CI 0.772 to 1.391The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
  • Combination Therapy vs Monotherapy · Log Rank · p = 0.2684 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.) · Hazard ratio (hr): 0.85 · 95% CI 0.636 to 1.134The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.
SecondaryObjective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Number · percentage of participants
Objective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
percentage of participantsCombination TherapyMonotherapyStandard of Care
Objective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC36.325.749.1
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.0005 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.58 · 95% CI 0.422 to 0.788The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = <0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.35 · 95% CI 0.253 to 0.485The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.
SecondaryObjective Response Rate (ORR), PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Number · percentage of participants
Objective Response Rate (ORR), PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC
percentage of participantsCombination TherapyMonotherapyStandard of Care
Objective Response Rate (ORR), PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC46.827.848.3
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.7708 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.94 · 95% CI 0.639 to 1.394The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = <0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.41 · 95% CI 0.268 to 0.610The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
SecondaryObjective Response Rate (ORR), PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Number · percentage of participants
Objective Response Rate (ORR), PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy
percentage of participantsCombination TherapyMonotherapyStandard of Care
Objective Response Rate (ORR), PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy20.422.650.4
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = <0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.24 · 95% CI 0.135 to 0.406The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
  • Combination Therapy vs Monotherapy · Regression, Logistic · p = 0.6195 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.86 · 95% CI 0.469 to 1.566The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
SecondaryObjective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population

Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR. unconfirmed responses are excluded.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (01NOV2017, a maximum of 3 years).
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population
percentage of participantsMonotherapy - PD-L1 HighMonotherapy - PD-L1 Low/NegativeMonotherapy - Total
Objective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population23.017.921.0
SecondaryDisease Control Rate (DCR) at 6 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) at 6 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
percentage of participantsCombination TherapyMonotherapyStandard of Care
Disease Control Rate (DCR) at 6 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC41.531.855.5
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.0002 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.56 · 95% CI 0.410 to 0.759The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = <0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.37 · 95% CI 0.267 to 0.500The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.
SecondaryDisease Control Rate (DCR) at 6 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) at 6 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC
percentage of participantsCombination TherapyMonotherapyStandard of Care
Disease Control Rate (DCR) at 6 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC49.834.453.1
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.4959 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.87 · 95% CI 0.590 to 1.291The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = 0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.46 · 95% CI 0.305 to 0.679The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
SecondaryDisease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy
percentage of participantsCombination TherapyMonotherapyStandard of Care
Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy29.227.759.1
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = <0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.27 · 95% CI 0.160 to 0.448The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
  • Combination Therapy vs Monotherapy · Regression, Logistic · p = 0.8074 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.07 · 95% CI 0.623 to 1.836The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
SecondaryDisease Control Rate (DCR) at 12 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) at 12 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
percentage of participantsCombination TherapyMonotherapyStandard of Care
Disease Control Rate (DCR) at 12 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC38.028.050.6
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.0008 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.59 · 95% CI 0.432 to 0.802The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = <0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.37 · 95% CI 0.270 to 0.512The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.
SecondaryDisease Control Rate (DCR) at 12 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC

Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) at 12 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC
percentage of participantsCombination TherapyMonotherapyStandard of Care
Disease Control Rate (DCR) at 12 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC47.330.648.8
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.7717 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.94 · 95% CI 0.639 to 1.394The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = 0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.46 · 95% CI 0.303 to 0.682The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
SecondaryDisease Control Rate (DCR) at 12 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy

Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) at 12 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy
percentage of participantsCombination TherapyMonotherapyStandard of Care
Disease Control Rate (DCR) at 12 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy24.124.153.3
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = <0.0001 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.26 · 95% CI 0.151 to 0.439The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
  • Combination Therapy vs Monotherapy · Regression, Logistic · p = 0.9692 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 0.99 · 95% CI 0.556 to 1.759The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.
SecondaryDuration of Response (DoR), Full Analysis Set

Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
Duration of Response (DoR), Full Analysis Set
MonthsCombination TherapyMonotherapyStandard of Care
Duration of Response (DoR), Full Analysis Set11.1 (4.3 to NA)9.3 (5.4 to NA)5.7 (3.7 to 9.3)
SecondaryDuration of Response (DoR), PD-L1-High Analysis Set

Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
Duration of Response (DoR), PD-L1-High Analysis Set
MonthsCombination TherapyMonotherapyStandard of Care
Duration of Response (DoR), PD-L1-High Analysis Set10.0 (3.8 to NA)18.5 (5.6 to NA)5.8 (3.7 to 11.5)
SecondaryDuration of Response (DoR), PD-L1-Low/Negative Analysis Set

Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).

Time frame:
Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Median · Months
Duration of Response (DoR), PD-L1-Low/Negative Analysis Set
MonthsCombination TherapyMonotherapyStandard of Care
Duration of Response (DoR), PD-L1-Low/Negative Analysis Set12.9 (5.5 to NA)5.6 (3.8 to NA)5.7 (3.9 to 8.2)
SecondarySerum Concentrations of Durvalumab, Pharmacokinetic Analysis Set

Blood samples were collected to determine the serum concentration of durvalumab.

Time frame:
Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.
Reported as:
Mean · μg/mL
Serum Concentrations of Durvalumab, Pharmacokinetic Analysis Set
μg/mLCombination TherapyMonotherapy
Week 0 - PredoseNA ± NANA ± NA
Week 0 - Postdose511 ± 338484 ± 162
Week 4 - Predose75.3 ± 84.478.9 ± 56.5
Week 12 - Predose125 ± 97.7144 ± 82.5
Week 12 - Postdose594 ± 298576 ± 233
Week 24 - Predose150 ± 94.4163 ± 82.5
Week 24 - Postdose604 ± 249600 ± 244
Follow-up Month 323.3 ± 5019.9 ± 18.4
SecondarySerum Concentrations of Tremelimumab, Pharmacokinetic Analysis Set

Blood samples were collected to determine the serum concentration of tremelimumab.

Time frame:
Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.
Reported as:
Mean · μg/mL
Serum Concentrations of Tremelimumab, Pharmacokinetic Analysis Set
μg/mLCombination Therapy
Week 0 - PredoseNA ± NA
Week 0 - Postdose24.0 ± 11.5
Week 4 - Predose3.75 ± 3.18
Week 12 - Predose5.43 ± 4.01
Week 12 - Postdose28.1 ± 13.2
Follow-up Month 30.943 ± 1.40
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab, Safety Analysis Set - ADA Evaluable Patients

Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Durvalumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.

Time frame:
At week 0, 4, 12 and 24, and at follow-up Month 3.
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab, Safety Analysis Set - ADA Evaluable Patients
ParticipantsCombination TherapyMonotherapy
ADA evaluable patients293302
ADA positive at any visit (ADA Prevalence)3731
Treatment-emergent ADA positive (ADA Incidence)2811
Treatment-boosted ADA01
Treatment-induced ADA (Positive Post-baseline only)2810
ADA Positive at Baseline only818
ADA Positive Post-baseline and Positive at Baseline13
Persistently Positive158
Transiently Positive145
nAb Positive at any visit32
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Tremelimumab, Safety Analysis Set - ADA Evaluable Patients

Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Tremelimumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.

Time frame:
At week 0, 4, 12 and at follow-up Month 3.
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Tremelimumab, Safety Analysis Set - ADA Evaluable Patients
ParticipantsCombination Therapy
ADA evaluable patients292
ADA positive at any visit (ADA Prevalence)64
Treatment-emergent ADA positive (ADA Incidence)54
Treatment-boosted ADA1
Treatment-induced ADA (Positive Post-baseline only)53
ADA Positive at Baseline only8
ADA Positive Post-baseline and Positive at Baseline3
Persistently Positive31
Transiently Positive25
nAb Positive at any visit50
SecondaryChange From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score. All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104). NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items "I feel weak all overall" and "I feel light-headed (dizzy)". The range of each item is 0-4. Higher score represent worse outcome.

Time frame:
At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Mean · Scores on a scale
Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
Scores on a scaleCombination TherapyMonotherapyStandard of Care
NFBLSI - 18 Score (Average overall visits)-3.7 ± 0.70-3.1 ± 0.76-5.2 ± 0.82
FACT-BL TOI (Average overall visits)-5.5 ± 0.87-3.9 ± 0.95-7.2 ± 1.02
FACT-BL Total score (Average overall visits)-7.2 ± 1.19-4.7 ± 1.30-8.8 ± 1.39
Statistical analysis
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.1617 (MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 1.5 · 95% CI -0.6 to 3.59
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.0578 (MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 2.1 · 95% CI -0.07 to 4.29
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.2003 (MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 1.7 · 95% CI -0.91 to 4.32
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.0178 (MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 3.3 · 95% CI 0.57 to 6.00
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.3765 (MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 1.6 · 95% CI -1.96 to 5.17
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.0300 (MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 4.1 · 95% CI 0.40 to 7.81
SecondaryChange From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score. All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104). NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items "I feel weak all overall" and "I feel light-headed (dizzy)". The range of each item is 0-4. Higher score represent worse

Time frame:
At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Mean · Scores on a scale
Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
Scores on a scaleCombination TherapyMonotherapyStandard of Care
NFBLSI - 18 Score (Average overall visits)-3.9 ± 0.85-2.0 ± 0.87-5.7 ± 0.95
FACT-BL TOI (Average overall visits)-5.8 ± 1.09-2.6 ± 1.11-8.0 ± 1.22
FACT-BL Total score (Average overall visits)-8.0 ± 1.47-2.7 ± 1.51-10.1 ± 1.65
Statistical analysis
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.1373 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 1.9 · 95% CI -0.6 to 4.36
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.0034 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 3.8 · 95% CI 1.26 to 6.27
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.1774 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 2.2 · 95% CI -1.00 to 5.39
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.0011 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 5.4 · 95% CI 2.19 to 8.65
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.3494 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 2.1 · 95% CI -2.27 to 6.38
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.0011 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): 7.3 · 95% CI 2.96 to 11.71
SecondaryChange From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score. All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104). NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items "I feel weak all overall" and "I feel light-headed (dizzy)". The range of each item is 0-4. Higher score represent worse

Time frame:
At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Mean · Scores on a scale
Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
Scores on a scaleCombination TherapyMonotherapyStandard of Care
NFBLSI - 18 Score (Average overall visits)-3.4 ± 1.01-3.8 ± 1.18-2.0 ± 1.16
FACT-BL TOI (Average overall visits)-4.9 ± 1.18-5.0 ± 1.39-3.0 ± 1.36
FACT-BL Total score (Average overall visits)-5.7 ± 1.62-6.5 ± 1.90-3.2 ± 1.86
Statistical analysis
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.3865 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): -1.3 · 95% CI -4.35 to 1.69
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.2840 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): -1.8 · 95% CI -5.05 to 1.49
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.2970 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): -1.9 · 95% CI -5.41 to 1.66
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.3026 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): -2.0 · 95% CI -5.85 to 1.83
  • Combination Therapy vs Standard of Care · Mixed Models Analysis · p = 0.3168 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): -2.5 · 95% CI -7.29 to 2.38
  • Monotherapy vs Standard of Care · Mixed Models Analysis · p = 0.2179 (MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.) · Mean difference (final values): -3.3 · 95% CI -8.51 to 1.96
SecondaryImprovement in Fatigue and Deterioration in Pain Per FACT-BL, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

Fatigue will be based on the question of "I have a lack of energy" and pain will be based on the question of "I have pain", according to GP1 and GP4 in PWB, respectively. Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL. Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.

Time frame:
At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Count of participants · Participants
Improvement in Fatigue and Deterioration in Pain Per FACT-BL, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
ParticipantsCombination TherapyMonotherapyStandard of Care
Patients with improvement in fatigue383724
Patient with deterioration in pain14213083
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.2419 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.4 · 95% CI 0.8 to 2.6The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood
  • Monotherapy vs Standard of Care · Regression, Logistic · p = 0.1553 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.5 · 95% CI 0.9 to 2.8The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.0003 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 2 · 95% CI 1.4 to 2.8The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = 0.0148 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.6 · 95% CI 1.1 to 2.3The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.
SecondaryImprovement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

Fatigue will be based on the question of "I have a lack of energy" and pain will be based on the question of "I have pain", according to GP1 and GP4 in PWB, respectively. Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL. Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.

Time frame:
At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Count of participants · Participants
Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
ParticipantsCombination TherapyMonotherapyStandard of Care
Patients with improvement in fatigue232414
Patient with deterioration in pain787151
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.2473 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.6 · 95% CI 0.7 to 3.4The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = 0.0148 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.7 · 95% CI 0.8 to 3.8The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.0090 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.9 · 95% CI 1.2 to 3.0The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood
  • Monotherapy vs Standard of Care · Regression, Logistic · p = 0.1510 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.4 · 95% CI 0.9 to 2.3The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.
SecondaryImprovement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC

Fatigue will be based on the question of "I have a lack of energy" and pain will be based on the question of "I have pain", according to GP1 and GP4 in PWB, respectively. Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL. Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.

Time frame:
At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Reported as:
Count of participants · Participants
Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC
ParticipantsCombination TherapyMonotherapyStandard of Care
Patients with improvement in fatigue151310
Patient with deterioration in pain645932
Statistical analysis
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.6763 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.2 · 95% CI 0.5 to 3.2The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.
  • Monotherapy vs Standard of Care · Regression, Logistic · p = 0.6539 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.2 · 95% CI 0.5 to 3.3The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.
  • Combination Therapy vs Standard of Care · Regression, Logistic · p = 0.0092 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 2.2 · 95% CI 1.2 to 4.0The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood
  • Monotherapy vs Standard of Care · Regression, Logistic · p = 0.0324 (P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.) · Odds ratio (or): 1.9 · 95% CI 1.1 to 3.5The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.

Adverse events

Collected over From first administration of study treatment up to 90 days after last dose of study medication or date of initiation of the first subsequent therapy, whichever occurs first, approximately 5 years. All-cause mortality, from screening up to data cut-off date (27JAN2020, approximately 5 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination Therapy255/342 (74.6%)179/340 (52.6%)306/340 (90%)
Monotherapy263/346 (76%)139/345 (40.3%)312/345 (90.4%)
Standard of Care270/344 (78.5%)125/313 (39.9%)299/313 (95.5%)
Most frequent serious events
Showing 10 of 278
Most frequent serious events
EventCombination TherapyMonotherapyStandard of Care
Urinary tract infectionInfections and infestations21/34017/34521/313
DiarrhoeaGastrointestinal disorders16/3402/3454/313
PyrexiaGeneral disorders16/3406/34513/313
PneumoniaInfections and infestations15/3408/3452/313
SepsisInfections and infestations3/34011/3454/313
AnaemiaBlood and lymphatic system disorders2/3407/3459/313
Acute kidney injuryRenal and urinary disorders6/3405/3458/313
ColitisGastrointestinal disorders7/3400/3450/313
ConstipationGastrointestinal disorders7/3403/3451/313
UrosepsisInfections and infestations7/3404/3452/313
Most frequent other events
Showing 10 of 52
Most frequent other events
EventCombination TherapyMonotherapyStandard of Care
AnaemiaBlood and lymphatic system disorders51/34058/345163/313
NauseaGastrointestinal disorders58/34074/345143/313
FatigueGeneral disorders89/34098/345101/313
DiarrhoeaGastrointestinal disorders99/34063/34555/313
NeutropeniaBlood and lymphatic system disorders0/3401/34589/313
ConstipationGastrointestinal disorders79/34066/34589/313
PruritusSkin and subcutaneous tissue disorders93/34053/34514/313
Decreased appetiteMetabolism and nutrition disorders72/34066/34580/313
AstheniaGeneral disorders54/34040/34568/313
PyrexiaGeneral disorders60/34050/34543/313

Baseline characteristics

Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.

Age, Continuous
Age, Continuous(years)Combination TherapyMonotherapyStandard of CareTotal
Age (years)66.4 ± 9.6066.3 ± 9.967.0 ± 9.3266.5 ± 9.60
Age, Customized
Age, Customized(Participants)Combination TherapyMonotherapyStandard of CareTotal
Age Group (Years) — <5019221455
Age Group (Years) — >= 50 - < 65118115119352
Age Group (Years) — >= 65 - < 75132141137410
Age Group (Years) — >= 75736874215
Sex: Female, Male
Sex: Female, Male(Participants)Combination TherapyMonotherapyStandard of CareTotal
Sex — Female869770253
Sex — Male256249274779
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Combination TherapyMonotherapyStandard of CareTotal
Ethnicity — Hispanic or Latino15141746
Ethnicity — Not Hispanic or Latino320329322971
Ethnicity — Unknown or Not Reported73515
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Combination TherapyMonotherapyStandard of CareTotal
Race — White253278260791
Race — Black or African American3306
Race — Asian726076208
Race — Native Hawaiian or other Pacific islander0000
Race — American Indian or Alaska Native0000
Race — Other134825
Race — Unknown or Not Reported1102
08

Study locations

222 sites
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06520, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Seattle, Washington 98101, United States
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Elizabeth Vale, 5112, Australia
  • Research Site
    Macquarie University, 2109, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Vienna, 1140, Austria
  • Research Site
    Brussels, 1000, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30380-472, Brazil
  • Research Site
    Ijuí, 98700-000, Brazil
  • Research Site
    Itajaí, 88301-220, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01209-000, Brazil
  • Research Site
    São Paulo, 01321-001, Brazil
  • Research Site
    São Paulo, 01509-900, Brazil
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Newmarket, Ontario L3Y 2P9, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Ottawa, Ontario K1H 1C4, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Québec, Quebec G1R 3S1, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100039, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130012, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Nanjing, 210008, China
  • Research Site
    Shanghai, 200000, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200072, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shanghai, 200127, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Tianjin, 300211, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xiamen, 361003, China
  • Research Site
    Århus C, 8000, Denmark
  • Research Site
    Herlev, 2730, Denmark
  • Research Site
    København Ø, 2100, Denmark
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Caen, 14076, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Marseille, 13273, France
  • Research Site
    Paris, 75475, France
  • Research Site
    Poitiers, 86021, France
  • Research Site
    Suresnes, 92151, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Düsseldorf, 40225, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    München, 81675, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Athens, 11528, Greece
  • Research Site
    Athens, 14564, Greece
  • Research Site
    Heraklion, 71110, Greece
  • Research Site
    Holargos, Athens, 155 62, Greece
  • Research Site
    Maroussi, Athens, 15125, Greece
  • Research Site
    Pátrai, 26500, Greece
  • Research Site
    Thessaloniki, 56 429, Greece

Showing the first 100 of 222 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bogemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suarez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. PubMed 32971005 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Jan 2020, 50 months.

Results were first posted in May 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2015
First posted
Aug 5, 2015
StartActual
Nov 2, 2015
Primary completionActual
Jan 27, 2020
CompletionEst.
Dec 31, 2026
Results first posted
May 13, 2021
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02516241
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 5, 2015
Start date
Nov 2, 2015
Primary completion
Jan 27, 2020
Completion
Dec 31, 2026 (estimated)
Results posted
May 13, 2021
Last update
Jul 14, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion